Yi‐Long Wu
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Oncology top 0.01%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Lung Cancer Treatments and Mutations 725
- Lung Cancer Diagnosis and Treatment 263
- Gastric Cancer Management and Outcomes 79
- Oncology 650
- Lung Cancer Research Studies 270
- Colorectal Cancer Treatments and Studies 215
- Cancer Immunotherapy and Biomarkers 129
- HER2/EGFR in Cancer Research 66
- Co-authors
- Tony MokJames Chih‐Hsin YangQing ZhouAlison ArmourSumitra ThongprasertMasahiro FukuokaWen‐Zhao ZhongHaiyi Jiang
- Journals
- Journal of Clinical Oncology (142 papers)Journal of Thoracic Oncology (139 papers)Annals of Oncology (133 papers)Lung Cancer (44 papers)Cancer Research (14 papers)
- Partner nations
- ChinaUnited StatesSouth Korea
In The Last Decade
Yi‐Long Wu
994 papers receiving 45.3k citations
Hit Papers
Peers
Comparison fields: 5 of 179
- Pulmonary and Respiratory Medicine 35.1k
- Oncology 28.8k
- Cancer Research 10.1k
- Molecular Biology 12.7k
- Pathology and Forensic Medicine 2.5k
Countries citing papers authored by Yi‐Long Wu
This map shows the geographic impact of Yi‐Long Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yi‐Long Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yi‐Long Wu more than expected).
Fields of papers citing papers by Yi‐Long Wu
This network shows the impact of papers produced by Yi‐Long Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yi‐Long Wu. The network helps show where Yi‐Long Wu may publish in the future.
Co-authors
The 25 scholars most cited alongside Yi‐Long Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 4 | |
| 4 | 2023 | 8 | |
| 5 | 2023 | 8 | |
| 6 | 2023 | 1 | |
| 7 | Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma Hit paper breakdown → | 2022 | 120 |
| 8 | Hypermethylation of the Nrf2 Promoter Induces Ferroptosis by Inhibiting the Nrf2-GPX4 Axis in COPD | 2021 | 1 |
| 9 | Nomogram Predicting Overall Survival of Resected Locally Advanced Rectal Cancer Patients with Neoadjuvant Chemoradiotherapy | 2020 | 1 |
| 10 | Assessing the value of preoperative medical clearance in patients with primary rhegmatogenous retinal detachment | 2019 | 0 |
| 11 | Effects of triptolide and methotrexate nanosuspensions on left ventricular remodeling in autoimmune myocarditis rats | 2019 | 1 |
| 12 | Dimeric c(RGD) peptide conjugated nanostructured lipid carriers for efficient delivery of Gambogic acid to breast cancer | 2019 | 1 |
| 13 | CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3) Hit paper breakdown → | 2018 | 349 |
| 14 | First-line afatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases | 2016 | 1 |
| 15 | Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer Hit paper breakdown → | 2016 | 397 |
| 16 | Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma Hit paper breakdown → | 2016 | 741 |
| 17 | Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy Hit paper breakdown → | 2015 | 367 |
| 18 | 2014 | 135 | |
| 19 | Enhanced and sustained topical ocular delivery of cyclosporine A in thermosensitive hyaluronic acid-based in situ forming microgels | 2013 | 2 |
| 20 | 2012 | 70 |
About Yi‐Long Wu
Yi‐Long Wu is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Hepatology, having authored 1.1k papers that have together received 46.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (725 papers), Lung Cancer Research Studies (270 papers), Lung Cancer Diagnosis and Treatment (263 papers), Colorectal Cancer Treatments and Studies (215 papers), Cancer Genomics and Diagnostics (143 papers), Cancer Immunotherapy and Biomarkers (129 papers), Gastric Cancer Management and Outcomes (79 papers) and HER2/EGFR in Cancer Research (66 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (35.1k citations), Oncology (28.8k citations), Cancer Research (10.1k citations), Molecular Biology (12.7k citations) and Pathology and Forensic Medicine (2.5k citations). Yi‐Long Wu has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Tony Mok, James Chih‐Hsin Yang, Qing Zhou, Alison Armour, Sumitra Thongprasert, Masahiro Fukuoka, Wen‐Zhao Zhong, Haiyi Jiang, Nagahiro Saijo and Kazuhiko Nakagawa. Their work appears in journals such as Journal of Clinical Oncology, Journal of Thoracic Oncology, Annals of Oncology, Lung Cancer and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.